Efficacy of bevacizumab in the treatment of refractory brain edema of metastatic tumors from different sources
Aim: This retrospective study investigated bevacizumab in treating refractory brain edema in patients with brain-metastatic tumors from different sources. Methods: From January 2013 to December 2019, 83 patients with brain metastases and refractory brain edema were treated with bevacizumab. They wer...
Saved in:
Published in | Neurological research (New York) Vol. 43; no. 12; pp. 955 - 960 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
England
Taylor & Francis
02.12.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Aim: This retrospective study investigated bevacizumab in treating refractory brain edema in patients with brain-metastatic tumors from different sources.
Methods: From January 2013 to December 2019, 83 patients with brain metastases and refractory brain edema were treated with bevacizumab. They were divided into lung cancer group and breast cancer group. The clinical data, the efficacy, and the side effects of bevacizumab were recorded. Magnetic resonance imaging was performed before and after bevacizumab treatment. The volume of tumor and brain edema were measured respectively.
Results: After treatment with bevacizumab, 72 cases of refractory brain edema were significantly relieved. The edema control rate was 93.75% in the lung cancer group and 77.14% in the breast cancer group (P < .05). The brain edema volume was significantly reduced after bevacizumab treatment from 198,286.84 ± 60,564.40 to 114,677.71 ± 42,337.38mm
3
(P < .01), and the edema index was reduced from 26.14 ± 7.24 to 17.18 ± 5.14 (P < .01). Hypertension was observed in 14 cases.
Conclusion: Bevacizumab could significantly reduce refractory brain edema with a control rate of 86.75%. The efficacy of bevacizumab in the treatment of refractory brain edema caused by lung cancer is better than that of breast cancer. |
---|---|
AbstractList | : This retrospective study investigated bevacizumab in treating refractory brain edema in patients with brain-metastatic tumors from different sources.
From January 2013 to December 2019, 83 patients with brain metastases and refractory brain edema were treated with bevacizumab. They were divided into lung cancer group and breast cancer group. The clinical data, the efficacy, and the side effects of bevacizumab were recorded. Magnetic resonance imaging was performed before and after bevacizumab treatment. The volume of tumor and brain edema were measured respectively.
After treatment with bevacizumab, 72 cases of refractory brain edema were significantly relieved. The edema control rate was 93.75% in the lung cancer group and 77.14% in the breast cancer group (P < .05). The brain edema volume was significantly reduced after bevacizumab treatment from 198,286.84 ± 60,564.40 to 114,677.71 ± 42,337.38mm
(P < .01), and the edema index was reduced from 26.14 ± 7.24 to 17.18 ± 5.14 (P < .01). Hypertension was observed in 14 cases.
Bevacizumab could significantly reduce refractory brain edema with a control rate of 86.75%. The efficacy of bevacizumab in the treatment of refractory brain edema caused by lung cancer is better than that of breast cancer. Aim: This retrospective study investigated bevacizumab in treating refractory brain edema in patients with brain-metastatic tumors from different sources. Methods: From January 2013 to December 2019, 83 patients with brain metastases and refractory brain edema were treated with bevacizumab. They were divided into lung cancer group and breast cancer group. The clinical data, the efficacy, and the side effects of bevacizumab were recorded. Magnetic resonance imaging was performed before and after bevacizumab treatment. The volume of tumor and brain edema were measured respectively. Results: After treatment with bevacizumab, 72 cases of refractory brain edema were significantly relieved. The edema control rate was 93.75% in the lung cancer group and 77.14% in the breast cancer group (P < .05). The brain edema volume was significantly reduced after bevacizumab treatment from 198,286.84 ± 60,564.40 to 114,677.71 ± 42,337.38mm 3 (P < .01), and the edema index was reduced from 26.14 ± 7.24 to 17.18 ± 5.14 (P < .01). Hypertension was observed in 14 cases. Conclusion: Bevacizumab could significantly reduce refractory brain edema with a control rate of 86.75%. The efficacy of bevacizumab in the treatment of refractory brain edema caused by lung cancer is better than that of breast cancer. |
Author | Zhang, Yuan Wang, Shiyong Ding, Weilong Bai, Xuexue |
Author_xml | – sequence: 1 givenname: Xuexue surname: Bai fullname: Bai, Xuexue organization: Jinan University – sequence: 2 givenname: Yuan surname: Zhang fullname: Zhang, Yuan organization: Peking University – sequence: 3 givenname: Weilong surname: Ding fullname: Ding, Weilong organization: Jinan University – sequence: 4 givenname: Shiyong surname: Wang fullname: Wang, Shiyong email: wangshiyong2525@126.com organization: Jinan University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34766548$$D View this record in MEDLINE/PubMed |
BookMark | eNo1kMtOwzAQRS0EoqXwCSD_QMpM7CTODlSVh4TEpvto4oxFUB0jxwWVr6cR7WoW99yR7rkS50MYWIhbhCWCgXvAEkuN-TKHHJdYa1NpOBNzrLTKUOXmXMwnJpugmbgax08ArHNTX4qZ0lVZFtrMxbB2rrdk9zI42fI32f5356mV_SDTB8sUmZLnIU15ZBfJphD3so10ILhjT1PiOdGYKPVWpp0PcZQuBi-73jmOU3sMu2h5vBYXjrYj3xzvQmye1pvVS_b2_vy6enzLrEaVsrI2oC2UeeHYlcpyAdhRpbkiQIJWqbZVFZka866DwlQOVKUKw1gDKFQLcff_9mvXeu6ar9h7ivvmtPsAPPwD_eBC9PQT4rZrEu23IR42DrYfG4XQTKqbk-pmUt0cVas_UlJyCA |
CitedBy_id | crossref_primary_10_1172_jci_insight_157347 crossref_primary_10_1080_21688370_2023_2292463 crossref_primary_10_3389_fonc_2022_1086821 crossref_primary_10_37349_etat_2022_00106 crossref_primary_10_1093_jjco_hyac197 crossref_primary_10_37349_etat_2022_00107 crossref_primary_10_1007_s00281_022_00945_5 crossref_primary_10_3390_cancers16112133 |
ContentType | Journal Article |
Copyright | 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2021 |
Copyright_xml | – notice: 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2021 |
DBID | 0YH CGR CUY CVF ECM EIF NPM |
DOI | 10.1080/01616412.2021.1948740 |
DatabaseName | Taylor & Francis Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 0YH name: Taylor & Francis Open Access url: https://www.tandfonline.com sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1743-1328 |
EndPage | 960 |
ExternalDocumentID | 34766548 1948740 |
Genre | Original Research Paper Journal Article |
GroupedDBID | --- 002 0BK 0YH 123 1~B 29N 36B 4.4 53G 5RE AAJNR AALUX AAMIU AAPUL AAQRR ABBKH ABEIZ ABLJU ABUPF ACENM ACGFO ACGOD ACLSK ADCVX ADFCX AECIN AENEX AFWLO AGDLA AGFJD AGRBW AGYJP AHMBA AIJEM AIRBT AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU AMDAE ARJSQ BLEHA BOHLJ CCCUG CS3 CXMEQ DU5 E01 EBS EMB EMOBN F5P H13 HCLVR HZ~ IPNFZ KYCEM L7B LJTGL M4Z MV1 P2P P76 P7A P7B PQEST PQQKQ RIG RNANH RVRKI SV3 TFL TFW TWFNG UEQFS .GJ AAFWK AAGKR AAOTW ABEJY ABKIK ABLIJ ABXYU ACIEZ ADXRV AEQML ALYBC AXVGA BALJE BEYMU BSQBA CGR CUY CVF ECM EIF EJD HMXZC M46 NPM TBQAZ TERGH TUROJ ZGI ZXP |
ID | FETCH-LOGICAL-c413t-69804c0625fef63ce501da74e7a01a0b33bb37a8912dd0587f037358e1900313 |
IEDL.DBID | 0YH |
ISSN | 0161-6412 |
IngestDate | Sat Sep 28 08:21:57 EDT 2024 Tue Jun 13 19:28:59 EDT 2023 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Keywords | lung cancer refractory brain edema breast cancer metastatic tumors Bevacizumab |
Language | English |
License | open-access: http://creativecommons.org/licenses/by-nc-nd/4.0/: http://creativecommons.org/licenses/by-nc-nd/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c413t-69804c0625fef63ce501da74e7a01a0b33bb37a8912dd0587f037358e1900313 |
OpenAccessLink | https://www.tandfonline.com/doi/abs/10.1080/01616412.2021.1948740 |
PMID | 34766548 |
PageCount | 6 |
ParticipantIDs | informaworld_taylorfrancis_310_1080_01616412_2021_1948740 pubmed_primary_34766548 |
PublicationCentury | 2000 |
PublicationDate | 2021-12-02 |
PublicationDateYYYYMMDD | 2021-12-02 |
PublicationDate_xml | – month: 12 year: 2021 text: 2021-12-02 day: 02 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Neurological research (New York) |
PublicationTitleAlternate | Neurol Res |
PublicationYear | 2021 |
Publisher | Taylor & Francis |
Publisher_xml | – name: Taylor & Francis |
SSID | ssj0019289 |
Score | 2.4159362 |
Snippet | Aim: This retrospective study investigated bevacizumab in treating refractory brain edema in patients with brain-metastatic tumors from different sources.... : This retrospective study investigated bevacizumab in treating refractory brain edema in patients with brain-metastatic tumors from different sources. From... |
SourceID | pubmed informaworld |
SourceType | Index Database Publisher |
StartPage | 955 |
SubjectTerms | Adult Angiogenesis Inhibitors - therapeutic use Bevacizumab Bevacizumab - therapeutic use Brain Edema - drug therapy Brain Edema - etiology Brain Neoplasms - complications Brain Neoplasms - drug therapy Brain Neoplasms - secondary breast cancer Breast Neoplasms - complications Breast Neoplasms - drug therapy Breast Neoplasms - secondary Female Humans lung cancer Lung Neoplasms - complications Lung Neoplasms - drug therapy Lung Neoplasms - secondary Male metastatic tumors Middle Aged refractory brain edema Retrospective Studies |
Title | Efficacy of bevacizumab in the treatment of refractory brain edema of metastatic tumors from different sources |
URI | https://www.tandfonline.com/doi/abs/10.1080/01616412.2021.1948740 https://www.ncbi.nlm.nih.gov/pubmed/34766548 |
Volume | 43 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5aQbyIb-uLHLyuJpt9ZI8iLUVo8VBBT0uSnUAP3Up3K9Rfbya7W6TgyctCCMlhNsl8k8x8HyH3IgGpObcBSKmDKLFpoAvuNp4CATKRifZPMeNJMnqLXt7jLpuwatMqMYa2DVGEP6txcytddRlxj4hSkohjGVXIH1wUjrJyu2QvdNAblzr7GG0eErLQq-DhkADHdEU8f02zxVi6BTa90xkekcMWLdKn5vcekx0oT8j-uH0PPyXlABkglFnThaUavpSZfa_mStNZSR2yo5s0cux3vnDp1XXWVKMwBIUC5gp75lArrCyaGVqv5otlRbHqhHbiKTVtrvirMzIdDqbPo6BVUAiMc051kGSSRYa5GMeCTYSBmPFCpRGkinHFtBBai1TJjIdFwWKZWiZSEUvgmSd1PCe9clHCJaFM6iwyRaxMAZFwDV5Io3lqMyEdhIE-yX7bLa_9fYNtxEFywTsm0tbmOdo8b23eJxeNkfPPhmEjF1GKqsjy6h-zXpMDbPrUk_CG9OrlCm4dgKj1nV8i7jt5Hf8AJAW99w |
link.rule.ids | 315,786,790,27533,27955,27956,59496,59497 |
linkProvider | Taylor & Francis |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELagSMCCeL_BA2vArp3EHhGiKo8yFQmmyHbOUoemqE2R4Nfjc1KEkJgYo5M9XOLcd-e77yPkQmSgLOc-AaVsIjOfJ7bk4eAZEKAyldl4FTN4yvrP8v4lffkxC4NtlZhD-4YoIv6r8XBjMXrREneFMCWTHOeouvwypOGoK7dMVlItNSZg7LX_fZOgu1EGD5ckuGYxxfPXNr8oS3-hzRh1eptko4WL9Lp5v1tkCaptsjpoL8R3SHWLFBDGfdCJpxbejRt9zsfG0lFFA7Sj333kaA_BcBrldT6oRWUICiWMDVrGUBscLRo5Ws_Hk-mM4tgJXain1LSp8c92ybB3O7zpJ62EQuJCdKqTTCsmHQtJjgefCQcp46XJJeSGccOsENaK3CjNu2XJUpV7JnKRKuA6sjrukU41qeCAUKaslq5MjStBivDAS-Usz70WKmAYOCT6p9-KOhYcfKMOUgi-oCJtfV6gz4vW54dkv3Fy8dZQbBRC5iiLrI7-ses5WesPB4_F493TwzFZR1PsQ-mekE49ncNpQBO1PYufyxcTfcBh |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LTxsxELaAShGXqrS0PErxgesWO_bu2kfUEoXyEIdUgtPKj7GUQzYo2VSCX4_HuxtVkThxXI3sw6zt-cae-T5CzkQBynIeMlDKZrIIZWY9jxvPgABVqMKmp5jbu2L8V_55yPtqwmVXVok5dGiJItJZjZv7yYe-Iu4cUUohObZRDfnPmIWjrNw2-ZBrqXGRs8fx-iFBD5MKHg7JcEzfxPPWNBuMpRtgMwWd0SfysUOL9KL9vXtkC-rPZHDbvYd_IfUlMkAY90zngVr4Z9z0ZTUzlk5rGpEdXZeRoz3GwkVS13mmFoUhKHiYGbTMoDHYWTR1tFnN5oslxa4T2ounNLS94l_uk8nocvJrnHUKCpmLwanJCq2YdCzmOAFCIRzkjHtTSigN44ZZIawVpVGaD71nuSoDE6XIFXCdSB2_kp16XsMBoUxZLZ3PjfMgRfzgXjnLy6CFihAGDon-329Vk-4bQisOUgneM5F2Pq_Q51Xn80PyrXVy9dQybFRClqiKrI7eMespGdz_HlU3V3fXx2QXLakKZfid7DSLFZxELNHYH2m1vAIRvL-K |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+bevacizumab+in+the+treatment+of+refractory+brain+edema+of+metastatic+tumors+from+different+sources&rft.jtitle=Neurological+research+%28New+York%29&rft.au=Bai%2C+Xuexue&rft.au=Zhang%2C+Yuan&rft.au=Ding%2C+Weilong&rft.au=Wang%2C+Shiyong&rft.date=2021-12-02&rft.pub=Taylor+%26+Francis&rft.issn=0161-6412&rft.eissn=1743-1328&rft.volume=43&rft.issue=12&rft.spage=955&rft.epage=960&rft_id=info:doi/10.1080%2F01616412.2021.1948740&rft.externalDBID=0YH&rft.externalDocID=1948740 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0161-6412&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0161-6412&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0161-6412&client=summon |